Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Goldman Sachs Downgrades Agios Pharma (AGIO) to Sell
July 30, 2021 6:55 AM EDTGoldman Sachs analyst Salveen Richter downgraded Agios Pharma (NASDAQ: AGIO) from Neutral to Sell with a price target of $39.00 (from $58.00).
The analyst comments "We downgrade AGIO from Neutral to Sell and lower our 12-month PT to $39 from $58. AGIO's late-stage clinical pipeline... More
